Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Using sequencing techniques, researchers associated 51 mutations in mitochondrial DNA with amyotrophic lateral sclerosis (ALS ...

In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest ...

A funding boost of more than £78 million will help UCL scientists working to develop a potential treatment for motor neurone disease, for which there is currently no cure and which affects 5,000 ...

Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.

Trace Neuroscience Launches with $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases, ...

Report Ocean, a leading strategic consulting, and Market research firm, in its recent study, estimated Global Amayotrophic Lateral Sclerosis (ALS) Market size by value at USD 902 million in 2023.

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that is marked by fasciculation, spasticity and progressive weakness of muscles, and results in difficulty speaking ...

Citation: Study identifies 51 amyotrophic lateral sclerosis-associated mutations that could help diagnose the disease (2024, October 31) retrieved 12 November 2024 from https://medicalxpress.com ...

Using sequencing techniques, researchers associated 51 mutations in mitochondrial DNA with amyotrophic lateral sclerosis (ALS), an incurable degenerative neurological disorder that leads to muscle ...